Biotech Nation featured Pacylex on its September 11th episode: "One Pill to Stop Many Cancers??? Dr. Michael Weickert, CEO, Pacylex Pharmaceuticals" with Dr. Moira Gunn interviewing Pacylex CEO Michael Weickert

CEO Michael Weickert will present Phase 1 safety and efficacy results for zelenirstat in the Orphan Drug indication of Acute Myeloid Leukemia (AML) at the World Orphan Drug Congress USA 2024, Apr 23-25, 2024.

Pacylex initiates a Phase 2a study in colorectal cancer with the first patient dosed with the recommended Phase 2 dose (RP2D). Prolonged Stable Disease of >6 months was observed in 57% (4/7) of the solid tumor patients.

Zelenirstat disrupts oxidative phosphorylation in cancer cells at AACR 2024. This defines a second potential mechanism which may account for early signs of zelenirstat anti-cancer activity in the Phase 1 study

CEO Michael Weickert will attend the upcoming BIO CEO & Investor Conference in NYC and will be meeting with investors regarding the company's Series B funding round.

Zelenirstat shows clinical benefit for colorectal and appendiceal cancer patients in Phase 1 Phase 1 results will be presented on January 20, 2024 at the ASCO Gastrointestinal Cancers Symposium

Pacylex passes major milestones in 2023 including: Phase I completion, no DLTs up to the target drug exposure, evidence of efficacy, and launching our Phase IIa.

Pacylex Pharmaceuticals Reports Safety and Efficacy Results from Its Phase 1 First-In-Human Study of Zelenirstat (PCLX-001) Pacylex’s CEO Will Present at Two Upcoming Life Science Investment Conferences